Bessemer funds trim Hinge Health (HNGE) stake with open-market sales

Q: What was the size of the Hinge Health (HNGE) share sales on February 13, 2026?

On February 13, 2026, the Bessemer funds sold 149,919 Hinge Health shares. BVP X sold 77,328 shares and BVP X Inst sold 72,591 shares at a weighted average price of $40.109, with trade prices between $39.50 and $40.722.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Hinge Health director and 10% owner Robinson Elliott, through Bessemer venture funds, reported indirect sales of the company’s Class A common stock. On February 12, 2026, Bessemer Venture Partners X L.P. sold 12,086 shares and Bessemer Venture Partners X Institutional L.P. sold 11,346 shares at a weighted average price of $40.096, in multiple trades between $40.025 and $40.115. On February 13, 2026, BVP X sold 77,328 shares and BVP X Inst sold 72,591 shares at a weighted average price of $40.109, with prices ranging from $39.50 to $40.722. Elliott has an indirect, passive economic interest in these Bessemer funds and disclaims beneficial ownership of their securities except to the extent of his pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Robinson Elliott

Role Director, 10% Owner

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	0	$0.00	$0.00
Sale	Class A Common Stock	0	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 0 shares (Indirect, See footnote)

Footnotes (3)

F1. On February 12, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 12,086 and 11,346 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $40.096. These shares were sold in multiple transactions at prices ranging from $40.025 to $40.115. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2. On February 13, 2026, BVP X and BVP X Inst sold 77,328 and 72,591 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $40.109. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.722. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

FAQ

What insider transaction did Hinge Health (HNGE) disclose in this Form 4?

The filing reports indirect sales of Hinge Health Class A shares by Bessemer funds. Two Bessemer Venture Partners funds associated with director and 10% owner Robinson Elliott sold shares over two days in open-market transactions at around $40 per share.

How many Hinge Health (HNGE) shares did the Bessemer funds sell on February 12, 2026?

On February 12, 2026, the Bessemer funds sold a total of 23,432 shares. Bessemer Venture Partners X L.P. sold 12,086 shares and Bessemer Venture Partners X Institutional L.P. sold 11,346 shares at a weighted average price of $40.096.

At what prices were the Hinge Health (HNGE) shares sold by the Bessemer funds?

The reported Hinge Health sales occurred around $40 per share. On February 12, 2026, trades ranged from $40.025 to $40.115, and on February 13, 2026, trades ranged from $39.50 to $40.722, based on weighted-average sale prices disclosed.

Does Robinson Elliott directly own the Hinge Health (HNGE) shares sold in this Form 4?

No, the shares were held by Bessemer Venture Partners funds, not by Elliott personally. He has an indirect, passive economic interest through partnership interests and expressly disclaims beneficial ownership except for any pecuniary interest in those fund holdings.

What is Robinson Elliott’s relationship to Hinge Health (HNGE)?

Robinson Elliott is reported as both a director and a 10% owner of Hinge Health. His reported ownership arises indirectly through Bessemer Venture Partners funds, where he is a partner, rather than through direct personal holdings in the company’s Class A common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/17/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last)

(First)

(Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT

10538

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/12/2026		S		0⁽¹⁾	D	$0	0	I	See footnote⁽¹⁾⁽³⁾
Class A Common Stock	02/13/2026		S		0⁽¹⁾	D	$0	0	I	See footnote⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On February 12, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 12,086 and 11,346 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $40.096. These shares were sold in multiple transactions at prices ranging from $40.025 to $40.115. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. On February 13, 2026, BVP X and BVP X Inst sold 77,328 and 72,591 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $40.109. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.722. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

	/s/ Augie Wilkinson, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR